Table 3.

Summary of studies in lymphoma patients evaluating the role of GnRH analogue in preserving female fertility

Study	Study group	Design	n	Regimen	Disease	POF (%)	Comments
Falorio et al. (3)	GnRH-a	Retrospective	61	ABVD & alkylating containing regimes	HL	-	Recovery of normal menses in 92% regardless of front-line chemotherapy regimens
Waxman et al.(28)	GnRH-a Control	Prospective, randomized	8	MVPP	LNH	75	Small sample size
			10			80
Blumenfeld et al.(29)	GnRH-a Control	Prospective, historical control group	16	Alkylating & non-alkylating containing regimens)	LNH	6	Longer follow-up in controls
			18			61
Dann et al. (30)	GnRH-a Control	Prospective, nonrandomized	7	Mega-CHOP	LNH	0	Small sample size, no statistical analysis
			6			16
Behringer et al.(27)	GnRH-a	Prospective randomized		Escalated BEACOPP	HL	-	This study was closed prematurely. Neither arm was able to ensure protection regarding FSH-based ovarian protection rates.
	OC
Blumenfeld et al.(26)	GnRH-a	Prospective study with historical controls	65	ABVD & procarbazine-containing regimens	HL	3	Not randomized. Effects probably only in younger patients < 37 years old
	Control		46			63
Huseret al.(31)	GnRH-a	Prospective case-control study	72	Alkylating & non-alkylating containing regimens)	HL	71	Reduction of ovarian failure risk in women with HL treated with less aggressive regimens plus a GnRH analogue
	Control		45			20

Adapted from Blumefeld Z et al. and Oktay K et al.^(24,25)

ABVD: Doxorubicin, bleomycin, vinblastine, dacarbazine; BEACOPP: Bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, prednisolone; MVPP: Mechlorethamine, vinblastine, procarbazine and prednisone; Mega-CHOP: Cyclophosphamide, doxorubicin, vincristine and prednisone; GnRH-a: Gonadotropin-releasing hormone analogs; OC: Oral contraceptives; HL: Hodgkin's lymphoma; NHL: Non-Hodgkin lymphoma